This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer’s Disease: A Randomised Controlled Trial


Phillips, Michelle A., Childs, Caroline E., Calder, Philip C., Rogers, Peter J.


International Journal Of Molecular Sciences, Volume: 16, No.: 10, Pages.: 24600-24613

Year of Publication



Findings from epidemiological and observational studies have indicated that diets high in omega-3 polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) may reduce the risk of cognitive decline and Alzheimer’s disease (AD). To determine if increasing intake of DHA and EPA through supplementation is beneficial to cognition and mood in individuals with cognitive impairment no dementia (CIND) or Alzheimer’s disease (AD) a four month, randomised, double-blind, placebo controlled study was conducted. Fifty-seven participants with CIND and nineteen with AD were randomised to receive either omega-3 PUFAs (600 mg EPA and 625 mg DHA per day) or placebo (olive oil) over a four month period. Elevating depleted levels of EPA and DHA through supplementation in individuals with CIND or AD was found to have negligible beneficial effect on their cognition or mood. These findings confirm an overall negligible benefit of omega-3 PUFA supplementation for those with cognitive impairment and dementia. More intervention studies need to be undertaken with longer study durations and larger sample sizes. It may prove fruitful to examine effects of different doses as well as effects in other dementia subtypes.;


3, acids, affect, aged, alzheimer disease, alzheimers disease ad, cognition disorders, cognitive impairment no dementia cind, dietary supplements, docosahexaenoic acid dha, docosahexaenoic acids, doubleblind method, drug effects, eicosapentaenoic acid, eicosapentaenoic acid epa, fatty, fatty acids omega3, female, humans, male, oil, olive, omega, omega3 fatty acids, or, physiopathology

Countries of Study


Types of Dementia

Alzheimer’s Disease, Mild Cognitive Impairment (MCI)

Types of Study

Randomised Controlled Trial

Type of Outcomes

Behaviour, Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions